{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T10:31:25Z","timestamp":1785148285552,"version":"3.55.0"},"reference-count":26,"publisher":"Japan Surgical Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Surg Case Rep"],"published-print":{"date-parts":[[2026]]},"DOI":"10.70352\/scrj.cr.26-0273","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T22:12:24Z","timestamp":1783030344000},"page":"n\/a","source":"Crossref","is-referenced-by-count":1,"title":["A Case of Pancreatic Cancer with High Tumor Mutation Burden Showing a Remarkable Response to Pembrolizumab"],"prefix":"10.70352","volume":"12","author":[{"given":"Kazuto","family":"Takata","sequence":"first","affiliation":[{"name":"Department of Gastroenterological Surgery, Graduate School of Life Sciences, Kumamoto University, Kumamoto, Kumamoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Kitano","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Graduate School of Life Sciences, Kumamoto University, Kumamoto, Kumamoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rumi","family":"Itoyama","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Graduate School of Life Sciences, Kumamoto University, Kumamoto, Kumamoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Graduate School of Life Sciences, Kumamoto University, Kumamoto, Kumamoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Miyamoto","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Graduate School of Life Sciences, Kumamoto University, Kumamoto, Kumamoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohisa","family":"Okabe","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Graduate School of Life Sciences, Kumamoto University, Kumamoto, Kumamoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromitsu","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Graduate School of Life Sciences, Kumamoto University, Kumamoto, Kumamoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhito","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Graduate School of Life Sciences, Kumamoto University, Kumamoto, Kumamoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0886-4618","authenticated-orcid":false,"given":"Masaaki","family":"Iwatsuki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Graduate School of Life Sciences, Kumamoto University, Kumamoto, Kumamoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"51119","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Del Chiaro M, Sugawara T, Karam SD, et al. Advances in the management of pancreatic cancer. BMJ 2023; 383: e073995.","DOI":"10.1136\/bmj-2022-073995"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 2020; 38: 1\u201310.","DOI":"10.1200\/JCO.19.02105"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228\u201347.","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Evans DB, Rich TA, Byrd DR, et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg 1992; 127: 1335\u20139.","DOI":"10.1001\/archsurg.1992.01420110083017"},{"key":"5","unstructured":"5) Brierley JDGM, Wittekind C. TNM Classification of Malignant Tumors, 8th ed. Wiley: Blackwell; 2017."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017; 357: 409\u201313.","DOI":"10.1126\/science.aan6733"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Lawlor RT, Mattiolo P, Mafficini A, et al. Tumor mutational burden as a potential biomarker for immunotherapy in pancreatic cancer: systematic review and still-open questions. Cancers (Basel) 2021; 13: 3119.","DOI":"10.3390\/cancers13133119"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Ta\u00efeb J, Sayah L, Heinrich K, et al. Efficacy of immune checkpoint inhibitors in microsatellite unstable\/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European Cohort. Eur J Cancer 2023; 188: 90\u20137.","DOI":"10.1016\/j.ejca.2023.04.012"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Cox RE Jr., Mahipal A, Chakrabarti S. A patient with locally advanced mismatch-repair-deficient pancreatic ductal adenocarcinoma successfully treated with neoadjuvant immunotherapy. Cureus 2021; 13: e14640.","DOI":"10.7759\/cureus.14640"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Zhang F, Li X, Liu H, et al. Unexpected favorable outcome to sintilimab monotherapy in a relapse pancreatic ductal adenocarcinoma patient with high tumor mutational burden: a case report. Anticancer Drugs 2022; 33: 975\u20138.","DOI":"10.1097\/CAD.0000000000001334"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Zhao L, Singh V, Ricca A, et al. Survival benefit of pembrolizumab for patients with pancreatic adenocarcinoma: a case series. J Med Cases 2022; 13: 240\u20133.","DOI":"10.14740\/jmc3918"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Zhu PF, Chen YW, Wang MX, et al. Tumor-mutation burden as a marker for immunotherapy of pancreatic cancer: the case report and literature review. Anticancer Drugs 2022; 33: e822\u20137.","DOI":"10.1097\/CAD.0000000000001232"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Anisetti B, Coston TW, Ahmed AK, et al. An excellent response of microsatellite instability-high pancreatic adenocarcinoma to pembrolizumab treatment: the role of circulating tumor DNA testing. Cureus 2023; 15: e37239.","DOI":"10.7759\/cureus.37239"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Dai M, Sheng J, Zhang Q, et al. Case report: partial response to single-agent pembrolizumab in a chemotherapy-resistant metastatic pancreatic cancer patient with a high tumor mutation burden. Front Oncol 2023; 13: 1118633.","DOI":"10.3389\/fonc.2023.1118633"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Han MY, Borazanci E. A rare case of sporadic mismatch repair deficient pancreatic ductal adenocarcinoma that responded to ipilimumab and nivolumab combination treatment: case report. J Gastrointest Oncol 2023; 14: 458\u201362.","DOI":"10.21037\/jgo-22-587"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Ngo P, Shanshal M, Rojan A. Immunotherapy in pancreatic cancer and the importance of tumour testing. BMJ Case Rep 2020; 13: e235774.","DOI":"10.1136\/bcr-2020-235774"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Grant RC, Denroche R, Jang GH, et al. Clinical and genomic characterisation of mismatch repair deficient pancreatic adenocarcinoma. Gut 2021; 70: 1894\u2013903.","DOI":"10.1136\/gutjnl-2020-320730"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Quintanilha JCF, Storandt MH, Graf RP, et al. Tumor mutational burden in real-world patients with pancreatic cancer: genomic alterations and predictive value for immune checkpoint inhibitor effectiveness. JCO Precis Oncol 2023; 7: e2300092.","DOI":"10.1200\/PO.23.00092"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Li K, Luo H, Huang L, et al. Microsatellite instability: a review of what the oncologist should know. Cancer Cell Int 2020; 20: 16.","DOI":"10.1186\/s12935-019-1091-8"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med 2018; 24: 556\u201362.","DOI":"10.1038\/s41591-018-0012-z"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Saldivar JC, Cortez D, Cimprich KA. The essential kinase ATR: ensuring faithful duplication of a challenging genome. Nat Rev Mol Cell Biol 2017; 18: 622\u201336.","DOI":"10.1038\/nrm.2017.67"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Giardiello FM, Allen JI, Axilbund JE, et al. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-Society Task Force on colorectal cancer. Gastroenterology 2014; 147: 502\u201326.","DOI":"10.1053\/j.gastro.2014.04.001"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Bonadona V, Bona\u00efti B, Olschwang S, et al. Cancer risks associated with germline mutations in <i>MLH1<\/i>, <i>MSH2<\/i>, and <i>MSH6<\/i> genes in Lynch syndrome. JAMA 2011; 305: 2304\u201310.","DOI":"10.1001\/jama.2011.743"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Li MM, Datto M, Duncavage EJ, et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn 2017; 19: 4\u201323.","DOI":"10.1016\/j.jmoldx.2016.10.002"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Matsubara J, Mukai K, Kondo T, et al. First-line genomic profiling in previously untreated advanced solid tumors for identification of targeted therapy opportunities. JAMA Netw Open 2023; 6: e2323336.","DOI":"10.1001\/jamanetworkopen.2023.23336"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Thapa B, Ahmed G, Szabo A, et al. Comprehensive genomic profiling: does timing matter? Front Oncol 2023; 13: 1025367.","DOI":"10.3389\/fonc.2023.1025367"}],"container-title":["Surgical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/scrj\/12\/1\/12_cr.26-0273\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T05:12:16Z","timestamp":1783141936000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/scrj\/12\/1\/12_cr.26-0273\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.70352\/scrj.cr.26-0273","relation":{},"ISSN":["2198-7793"],"issn-type":[{"value":"2198-7793","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"cr.26-0273"}}